<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1323">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113969</url>
  </required_header>
  <id_info>
    <org_study_id>SA12I2153</org_study_id>
    <nct_id>NCT02113969</nct_id>
  </id_info>
  <brief_title>Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol</brief_title>
  <official_title>Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servicio de Salud Metropolitano Sur Oriente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Servicio de Salud Metropolitano Sur Oriente</source>
  <oversight_info>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <authority>Chile: Comité de Ética Científico</authority>
    <authority>Chile: Institutional Review Board</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>Chile: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genital prolapse is a common condition (up 20%), affecting the quality of life. Treatment
      can be surgical or conservative using vaginal pessaries. These devices are introduced into
      the vagina aiming to reduces the prolapse.

      Pessaries have shown effectiveness in improving symptoms and quality of life. There are no
      randomized studies comparing them with surgery. This study design would be difficult to
      perform, because the inclusion criteria for both treatments are different. There are no
      currently standard protocols for the use of pessaries. This makes harder to widespread the
      usage of this conservative treatment.

      The aim of the investigators is to identify variables that influence the success of
      conservative management of genital prolapse at 1 year of follow up. Using these variables
      and an expert panel opinion the investigators will develop a standardized protocol for
      pessary management.

      Chile has a primary gynecological care system based midwives. Therefore having algorithms
      for pessaries usage becomes relevant. This algorithm can be implemented with basic training.
      This would increase the respond capacity, by the health care system to this disease,
      considering the scarce access to surgery.

      The investigators hypothesis is: It is possible to generate a standardized protocol of
      conservative management of symptomatic genital prolapse in patient's beneficiary of public
      health system in Santiago, Chile, using pessaries through a prospective cohort study based
      in the success of these devices with 1 year of follow up, measured with questionnaires of
      symptoms, quality of life and sexuality
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Quality of Life changes in pessary users for symptomatic Pelvic Organs Prolapse</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline, 6 and 12 month the Chilean Version of the P-QoL survey will be applied to describe the QoL changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Disorders symptoms changes in pessary users for symptomatic Pelvic Organs Prolapse</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline, 6 and 12 month the Chilean Version of the Pelvic Distress Inventory - 20 (PDFI-20) survey will be applied to describe the symptoms changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual response changes in pessary sexually active women users for symptomatic Pelvic Organs Prolapse</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline, 6 and 12 month the Chilean Version of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) survey will be applied to describe the Sexually response changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective impression of improvement after pessary use for symptomatic Pelvic Organs Prolapse</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline, 6 and 12 month the Patient Global Impression of Improvement (PGI-I) survey will be applied to describe the subjective improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful usage of pessary</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>If an enrolled patients is still using the pessary as the treatment for the pelvic organ prolapse will be considered as &quot;successful&quot;.
Risk factors for unsuccessful pessary used will be measure using baseline characteristics.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Vaginal Pessary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pessary users for at least 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vaginal Pessary</intervention_name>
    <description>Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.</description>
    <arm_group_label>Vaginal Pessary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic Pelvic Organ Prolapse

          -  Commitment to attend controls

          -  Current negative cervical cytology

          -  Informed consent signed

        Exclusion Criteria:

          -  Urinary incontinence as the only Pessary Indication

          -  Vaginal bleeding of undetermined cause

          -  Unable to return to controls
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Pizarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial Dr. Sotero del Rio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernardita Blumel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Asistencial Dr. Sotero del Rio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvana Gonzalez, Midwife</last_name>
    <role>Study Chair</role>
    <affiliation>Complejo Asistencial Dr. Sotero del Rio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Pattillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>H. Dr. Sotero del Rio; Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Pizarro, MD</last_name>
    <phone>216 583-6220</phone>
    <email>jpizarro@med.puc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernardita Blumel, MD</last_name>
    <phone>56 9 82328165</phone>
    <email>bernarditablumel@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unidad de Uroginecologia, Complejo Asistencial Dr. Sotero del Rio</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Pizarro, MD</last_name>
      <phone>216-583-6220</phone>
      <email>jpizarro@med.puc.cl</email>
    </contact>
    <contact_backup>
      <last_name>Bernardita Blumel, MD</last_name>
      <phone>56 9 8232 8165</phone>
      <email>bernarditablumel@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Pizarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardita Blumel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvana Gonzalez, Midwife</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Cuevas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Pattillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Arellano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Pineda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Miranda, Md, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oslando Padilla, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard B Goldman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 17, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvic Organ Prolapse</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Symptoms</keyword>
  <keyword>Pessary</keyword>
  <keyword>Treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
